Abstract | PURPOSE: RESULTS:
Reveromycin A induced apoptosis specifically in osteoclasts in vitro. Although reveromycin A did not inhibit SBC-5 cell proliferation, it suppressed the expression of parathyroid hormone-related peptide. Intravenous inoculation of SBC-5 cells in natural killer cell-depleted severe combined immunodeficient mice produced experimental metastases in multiple organs, including the bone. Daily administration of reveromycin A inhibited the bone metastasis, but not visceral metastasis, in a dose-dependent manner. Histologic analyses revealed that although treatment with reveromycin A did not affect the number of proliferating tumor cells, it decreased the number of osteoclasts and increased apoptotic cells in bone lesions. CONCLUSIONS:
|
Authors | Hiroaki Muguruma, Seiji Yano, Soji Kakiuchi, Hisanori Uehara, Makoto Kawatani, Hiroyuki Osada, Saburo Sone |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 11
Issue 24 Pt 1
Pg. 8822-8
(Dec 15 2005)
ISSN: 1078-0432 [Print] United States |
PMID | 16361571
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibiotics, Antineoplastic
- Parathyroid Hormone-Related Protein
- Pyrans
- Spiro Compounds
- Vascular Endothelial Growth Factor A
- reveromycin A
|
Topics |
- Animals
- Antibiotics, Antineoplastic
(therapeutic use)
- Bone Neoplasms
(prevention & control, secondary)
- Carcinoma, Small Cell
(drug therapy, metabolism, secondary)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Humans
- Lung Neoplasms
(drug therapy, metabolism, pathology)
- Mice
- Mice, SCID
- Osteoclasts
(drug effects, pathology)
- Parathyroid Hormone-Related Protein
(metabolism)
- Pyrans
(pharmacology, therapeutic use)
- Spiro Compounds
(pharmacology, therapeutic use)
- Vascular Endothelial Growth Factor A
(metabolism)
|